Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial.

Jesús Sojo-DoradoInmaculada López-HernándezAlicia Hernández-TorresPilar Retamar-GentilEsperanza Merino de LucasLaura Escolà-VergéElena BereciartuaElisa García-VázquezVicente PintadoLucía Boix-PalopClara Natera-KindelánLuisa SorlíNuria BorrellConcha Amador-ProusEvelyn ShawAlfredo Jover-SaenzJose MolinaRosa M Martínez-ÁlvarezCarlos J DueñasJorge Calvo-MontesMaría LecuonaVirginia PomarIrene BorregueroVirginia Palomo-JiménezFernando Docobo-PérezAlvaro Pascual Jesús Rodríguez-Bañonull null

Published in: The Journal of antimicrobial chemotherapy (2023)

Fosfomycin trometamol might be a reasonable option as step-down therapy in patients with BUTI due to MDR-Ec but the higher rate of relapses would need further assessment.

Keyphrases

urinary tract infection
escherichia coli
multidrug resistant
climate change
randomized controlled trial
systematic review
gram negative
klebsiella pneumoniae